Alecensa® (alectinib)
for Lung Cancer

Alecensa (alectinib) is an oral kinase inhibitor used in adults with non-small cell lung cancer (NSCLC) caused by an abnormal ALK gene. It is approved as adjuvant therapy after tumor removal or for metastatic cases. Alecensa targets ALK and RET tyrosine kinases helping to block cancer cell growth and reduce the risk of recurrence or spread.

Heart